trending Market Intelligence /marketintelligence/en/news-insights/trending/WqlZINOFSA2jSwW7eN4izg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Another proxy firm backs CytRx reverse stock split plan

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Another proxy firm backs CytRx reverse stock split plan

Institutional Shareholder Services Inc. recommended that CytRx Corp. shareholders vote in favor of the company's proposed reverse stock split at the upcoming Oct. 17 meeting.

The proxy advisory firm was echoing the same advice from Glass Lewis & Co.

The biopharmaceutical company is seeking shareholder approval to implement a 1-for-6 reverse stock split of both its authorized common and preferred stock in an attempt to regain compliance with Nasdaq's $1 minimum bid price requirement to maintain listing on the exchange.